| | |

Study Highlights How Genes Impact Mesothelioma Survival

ByAlex Strauss
Genes impact mesothelioma survival

A new National Cancer Institute study shines a light on some of the ways genes impact mesothelioma survival. It could have important implications for mesothelioma treatment.

The study was led by prominent mesothelioma researcher Raffit Hassan, MD. It focused on genetic mutations that may make certain mesothelioma patients more sensitive to chemotherapy.

Genes, Genotype, and Mesothelioma Treatment

A mesothelioma patient’s unique collection of genes, including genetic mutations, is known as their genotype.

Genes impact mesothelioma survival in a variety of ways. Tumor suppressor genes are supposed to help keep tumors from forming. People with mutations on these genes may be more likely to get malignant mesothelioma.

Other genes influence the cancer’s ability to “hide” from detection by the immune system. Some new treatments for mesothelioma focus on trying to offset the effects of these mutations.

DNA Repair Genes Impact Mesothelioma Survival

In the current mesothelioma study, Dr. Hassan and his colleagues analyzed how DNA repair genes impact mesothelioma survival.

DNA repair genes are supposed to help fix problems that can naturally crop up in the DNA during a cell’s life. Part of their job is to help keep tumors from forming in the first place.

But the new study shows that mesothelioma patients with mutations in these genes may also be more susceptible to chemotherapy. When chemotherapy damages DNA in these patients’ mesothelioma cells, the cells may not be able to recover.

As a result, it appears that these genes impact mesothelioma survival positively.

“Among 385 patients treated with platinum chemotherapy, median overall survival was significantly longer for patients with loss-of-function mutations in any of the targeted genes compared with patients with no such mutation,” writes Dr. Hassan.

The Effect of Genotype on Mesothelioma Prognosis

Apparently genes impact mesothelioma survival differently depending on what type of mesothelioma a patient has.

The study found that pleural mesothelioma patients with loss-of-function genetic mutations who had chemotherapy had a median survival of 7.9 years versus 2.4 year. Pleural mesothelioma affects the lining around the lungs. It is the most common type.

In contrast, There was no significant survival difference in peritoneal mesothelioma patients with or without these same loss-of-function mutations. Peritoneal mesothelioma impacts the lining around the abdomen. About a fifth of mesothelioma cases are this kind.

The researchers conclude: “Patients with pleural mesothelioma with inherited mutations in DNA repair and other tumor suppressor genes appear to particularly benefit from platinum chemotherapy compared with patients without inherited mutations.”

In general, chemotherapy for mesothelioma is only moderately effective. It typically extends survival by only a few months. Knowing ahead of time which patients are most likely to benefit could help in treatment planning.

Source:

Hassan, R, et al, “Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy”, April 11, 2019, Proc Natl Acad Sci USA, Epub ahead of print, https://www.pnas.org/content/early/2019/04/10/1821510116

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…